Antithrombotic Activities of a Novel Yogurt Drink | NCT05318911 | Trialant

Antithrombotic Activities of a Novel Yogurt Drink | NCT05318911 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Supplement Group	Active Comparator	10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of novel yogurt drink per day for a period of 28 days. Then, after a 2-week washout period in which the subjects do not take any yoghurt drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis.	Dietary Supplement: Novel yogurt drink
Placebo Group	Placebo Comparator	10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of placebo drink per day for a period of 28 days. Then, after a 2-week washout period in which the subjects do not take any placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis.	Other: Placebo Drink

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Platelet aggregation of PRP samples in the presence of PAF	Platelet aggregation of participants' platelet-rich plasma samples (PRP) in the presence of the platelet agonist PAF will be assessed, using EC50 as a parameter.	Participants' platelet activity will be assessed for up to roughly 6 months through study completion
Screening of plasma levels of cholesterol ( PL, LDL, HDL, VLDL).	Platelet-rich plasma (PRP) levels of cholesterol ( PL, LDL, HDL, VLDL levels) will be assessed.	The outcomes of this testing will be assessed for up to roughly 6 months through study completion.
Screening plasma levels of inflammatory markers.	Platelet-rich plasma levels of the inflammatory markers (IL-6, CRP. TNF-α, VEGF, VCAM-1 and PAFR) will all be screened.	The outcomes of this testing will be assessed for up to roughly 6 months through study completion.
Screening plasma levels of triglycerides.	PRP levels of triglycerides will also be screened.	The outcomes of this testing will be assessed for up to roughly 6 months through study completion.

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
30619728	Background	Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. MethodsX. 2018 Dec 26;6:63-70. doi: 10.1016/j.mex.2018.12.012. eCollection 2019.